Notable Insider Report: Friedhelm Blobel the President & CEO of SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) Sold 70,000 Shares

November 23, 2016 - By Nellie Frank

Notable Insider Report: Friedhelm Blobel the President & CEO of SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) Sold 70,000 Shares

Friedhelm Blobel Insider Sell

Mr. Friedhelm Blobel, the key President & CEO at Sciclone Pharmaceuticals Inc has not a long ago been involved with a sale of 70,000 shares of the ‘s company, valued at $10.2 per share. The total sell value is of of $715,179 USD. This is not his first insider trade, in the last month, he sold another 70,000 shares worth $680,030 USD. Friedhelm Blobel currently has 0.17% of the company’s stock market capitalization with ownership of 86,784 shares. 

Insitutional Activity: The institutional sentiment increased to 1.34 in Q2 2016. Its up 0.16, from 1.18 in 2016Q1. The ratio increased, as 26 funds sold all SciClone Pharmaceuticals, Inc. shares owned while 41 reduced positions. 32 funds bought stakes while 47 increased positions. They now own 38.22 million shares or 3.91% more from 36.79 million shares in 2016Q1.

Amer Interest Grp holds 0% or 37,258 shares in its portfolio. Acadian Asset Management Ltd Company reported 1.99M shares or 0.13% of all its holdings. Proshare Advsr Ltd Llc owns 44,398 shares or 0.01% of their US portfolio. Zebra Capital Mngmt Lc accumulated 0.24% or 53,177 shares. Virginia Retirement System Et Al owns 24,200 shares or 0% of their US portfolio. Shinko Asset Management has invested 0.03% of its portfolio in SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN). Comerica National Bank & Trust owns 49,872 shares or 0% of their US portfolio. Hutchin Hill Limited Partnership, a New York-based fund reported 88,300 shares. State Street Corporation accumulated 1.25M shares or 0% of the stock. Spark Management Limited owns 14,700 shares or 0.02% of their US portfolio. The California-based California Public Employees Retirement Systems has invested 0% in SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN). Hanseatic Mngmt Serv Inc accumulated 62 shares or 0% of the stock. Morgan Stanley accumulated 0% or 430,149 shares. Dimensional Fund Advsr L P has 0.02% invested in the company for 2.61M shares. Panagora Asset Mgmt, a Massachusetts-based fund reported 150,511 shares.

Insider Transactions: Since August 12, 2016, the stock had 0 insider buys, and 13 insider sales for $10.41 million net activity. $1.24M worth of shares were sold by Hawkins Richard J on Friday, August 12. On Friday, November 11 the insider Blobel Friedhelm sold $308,138. $257,896 worth of SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) shares were sold by CHANG NANCY T. The insider Zhao Hong sold $421,605. Cheung Wilson Wai-Shun sold 1,475 shares worth $14,750. Meng Chuncai sold $323,574 worth of stock. King Robert had sold 48,667 shares worth $506,623 on Friday, August 12.

The stock decreased 1.93% or $0.2 during the last trading session, hitting $10.15. About 489,312 shares traded hands or 33.02% up from the average. SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) has declined 20.14% since April 21, 2016 and is downtrending. It has underperformed by 25.47% the S&P500.

SciClone Pharmaceuticals, Inc. is a pharmaceutical company. The company has a market cap of $523.25 million. The Company’s product portfolio of therapies includes oncology, infectious diseases and cardiovascular disorders. It has a 13.56 P/E ratio. The Firm operates in two divisions: China and the Rest of the World, including its activities in the United States and Hong Kong.

According to Zacks Investment Research, “Sciclone Pharmaceuticals, Inc. develops and commercializes novel medicines for treating a broad range of the world’s most serious diseases. They have focused their current product development and commercial activities on the following diseases: hepatitis C, hepatocellular carcinoma, malignant melanoma, hepatitis B, HIV, drug-resistant tuberculosis, cystic fibrosis and others.”

Analysts await SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) to report earnings on March, 9.

More notable recent SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) news were published by: Prnewswire.com which released: “SciClone Pharmaceuticals To Report Third Quarter 2016 Financial Results On ..” on October 25, 2016, also Marketwatch.com with their article: “Virtual Stock Exchange” published on October 28, 2009, Quotes.Wsj.com published: “DOW JONES, A NEWS CORP COMPANY” on February 12, 2011. More interesting news about SciClone Pharmaceuticals, Inc. (NASDAQ:SCLN) were released by: Prnewswire.com and their article: “SciClone Reports Third Quarter 2016 Financial Results” published on November 09, 2016 as well as Prnewswire.com‘s news article titled: “Soligenix and SciClone Establish Regional Licensing Agreement for SGX942, a ..” with publication date: September 12, 2016.

SCLN Company Profile

SciClone Pharmaceuticals, Inc. (SciClone), incorporated on June 26, 2003, is a pharmaceutical company. The Company’s product portfolio of therapies includes oncology, infectious diseases and cardiovascular disorders. The Company’s business is focused primarily in the People’s Republic of China. The Firm operates in two divisions: China and the Rest of the World, including its activities in the United States and Hong Kong. The Company’s lead product ZADAXIN (thymalfasin) is approved in over 30 countries, which is used for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV), and certain cancers according to the local regulatory approvals, and for use as an immune system enhancer. In addition to ZADAXIN, SciClone markets approximately seven partnered and in-licensed products in China. The Firm sells ZADAXIN in various international markets through its subsidiary, SciClone Pharmaceuticals International Ltd. (SPIL).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Tags: , ,

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>